Apyx Medical Corporation (NASDAQ:APYX) Short Interest Up 22.3% in February

Apyx Medical Corporation (NASDAQ:APYX) was the target of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 173,573 shares, a growth of 22.3% from the February 12th total of 141,982 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 64,528 shares, the short-interest ratio is presently 2.7 days. Based on an average daily trading volume, of 64,528 shares, the short-interest ratio is presently 2.7 days. Approximately 0.5% of the company’s shares are sold short.

Analysts Set New Price Targets

APYX has been the subject of several recent analyst reports. Wall Street Zen raised shares of Apyx Medical to a “hold” rating in a research note on Saturday, November 22nd. Craig Hallum raised their price objective on Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. BTIG Research raised Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research report on Wednesday, March 11th. Roth Mkm assumed coverage on Apyx Medical in a research note on Monday, December 15th. They issued a “buy” rating and a $6.00 target price for the company. Finally, Zacks Research upgraded Apyx Medical to a “hold” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Apyx Medical currently has a consensus rating of “Moderate Buy” and an average price target of $6.50.

Apyx Medical Stock Performance

NASDAQ:APYX opened at $3.63 on Monday. The company has a market cap of $151.84 million, a P/E ratio of -13.44 and a beta of 1.61. The firm’s 50 day moving average is $3.75 and its two-hundred day moving average is $3.34. Apyx Medical has a fifty-two week low of $0.76 and a fifty-two week high of $4.50. The company has a quick ratio of 4.26, a current ratio of 5.00 and a debt-to-equity ratio of 2.35.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $19.16 million during the quarter, compared to analysts’ expectations of $19.12 million. Apyx Medical had a negative net margin of 21.22% and a negative return on equity of 114.95%. Analysts expect that Apyx Medical will post -0.68 EPS for the current year.

Institutional Investors Weigh In On Apyx Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC raised its holdings in shares of Apyx Medical by 9.4% in the 2nd quarter. Kingsview Wealth Management LLC now owns 191,597 shares of the company’s stock worth $431,000 after purchasing an additional 16,502 shares during the period. Fisher Asset Management LLC purchased a new stake in shares of Apyx Medical during the 2nd quarter worth about $34,000. Nantahala Capital Management LLC increased its position in Apyx Medical by 2.5% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after purchasing an additional 80,000 shares in the last quarter. Osaic Holdings Inc. acquired a new stake in Apyx Medical during the 2nd quarter worth approximately $50,000. Finally, Salem Investment Counselors Inc. purchased a new position in Apyx Medical in the third quarter valued at approximately $97,000. 55.33% of the stock is currently owned by institutional investors and hedge funds.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.